Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB/ SE0000872095 /
SOBI
|
2024-05-14 5:29:41 PM
|
Chg.
-
|
Volume |
Bid5:29:41 PM |
Ask5:29:41 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
283.40SEK
|
-
|
835,676
Turnover: 219.64 mill. |
282.40Bid Size: 675 |
282.80Ask Size: 429 |
100.43 bill.SEK |
- |
37.94 |
Business description
Swedish Orphan Biovitrum AB is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families.
Management board & Supervisory board
| CEO |
| Guido Oelkers |
| Management board |
| Henrik Stenqvist, Lydia Abad-Franch, Duane H. Barnes, Lena Bjurner, Sofiane Fahmy, Torbjörn Hallberg, Mahmood Ladha, Norbert Oppitz, Daniel Rankin, Armin Reininger, Christine Wesström |
| Supervisory board |
| Annette Clancy, Christophe Bourdon, Helena Saxon, Staffan Schüberg, Katy Mazibuko, Mats Lek, Anders Ullman, Filippa Stenberg |
Company data
| Name: |
Swedish Orphan Biovitrum AB |
| Address: |
Tomtebodavägen 23A,Solna 112 76 |
| Phone: |
+46-8-697-2000 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.sobi.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
42.16% |
| IPO date: |
- |
Company calendar
|
CW 29 | 2024-07-16
Interim Report 2nd Quarter/6 Months
|
|
CW 43 | 2024-10-24
Interim Report 3rd Quarter/9 Months
|
